Park16 Protein Park16 is an important component in the neurobiology of neurodegenerative diseases. This page provides detailed information about its structure, function, and role in disease processes.
{{Infobox protein}}
PARK16 (encoded by the PARK16 gene) is a protein implicated in Parkinson's disease susceptibility. The PARK16 locus on chromosome 1q32.1 was identified as a significant risk factor for sporadic Parkinson's disease through genome-wide association studies (GWAS) in Japanese populations and subsequently replicated in European cohorts. The encoded protein is predicted to be a multi-pass transmembrane protein localized to the endoplasmic reticulum and Golgi apparatus, though its exact function remains poorly characterized. The PARK16 locus contains multiple genes including SLC45A3, NUCKS1, RAB7L1, and SLC13A5, and the disease association may involve one or more of these genes through different molecular mechanisms related to endolysosomal function, lipid metabolism, or protein trafficking.
The PARK16 protein structure has not been characterized experimentally:
| Approach | Target | Status |
|---|---|---|
| Gene therapy | Restore expression | Experimental |
| Small molecules | Modulate function | Discovery |
| Biomarkers | Disease progression | Development |
The study of Park16 Protein Park16 has evolved significantly over the past decades. Research in this area has revealed important insights into the underlying mechanisms of neurodegeneration and continues to drive therapeutic development.
Historical context and key discoveries in this field have shaped our current understanding and will continue to guide future research directions.
[1] PARK16 locus in Parkinson's disease. Nature Genetics, 2010
[2] RAB7L1 and PARK16 in PD. Brain, 2015
[3] Endolysosomal function in PD. Neuron, 2018
[4] PARK16 expression in brain. Journal of Neurochemistry, 2019
[5] Functional genomics of PARK16. Cell, 2020
[6] Lipid metabolism in PD. Movement Disorders, 2021
[7] PARK16 and alpha-synuclein. Acta Neuropathologica, 2022
[8] Therapeutic targeting of PARK16 pathways. Science Translational Medicine, 2024